Title |
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
|
---|---|
Published in |
BMC Cancer, April 2012
|
DOI | 10.1186/1471-2407-12-144 |
Pubmed ID | |
Authors |
Carl Christoph Schimanski, Markus Möhler, Michael Schön, Eric van Cutsem, Richard Greil, Wolf Otto Bechstein, Susanna Hegewisch-Becker, Götz von Wichert, Matthias Vöhringer, Michael Heike, Volker Heinemann, Marc Peeters, Stephan Kanzler, Stefan Kasper, Friedrich Overkamp, Jan Schröder, Daniel Seehofer, Frank Kullmann, Bernhard Linz, Irene Schmidtmann, Victoria Smith-Machnow, Ines Gockel, Hauke Lang, Peter R Galle |
Abstract |
15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 86 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 16 | 19% |
Student > Master | 9 | 10% |
Other | 7 | 8% |
Student > Bachelor | 7 | 8% |
Student > Doctoral Student | 5 | 6% |
Other | 19 | 22% |
Unknown | 23 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 37% |
Nursing and Health Professions | 7 | 8% |
Agricultural and Biological Sciences | 5 | 6% |
Biochemistry, Genetics and Molecular Biology | 4 | 5% |
Chemistry | 4 | 5% |
Other | 10 | 12% |
Unknown | 24 | 28% |